151 related articles for article (PubMed ID: 18793576)
1. Exenatide pharmacokinetics in healthy Chinese subjects.
Zhao X; Cui YM; Zhou Y; Zhang HL; Yeo KP; Linnebjerg H; Tham LS; Kothare P; Teng LL; Mace K; Soon D
Int J Clin Pharmacol Ther; 2008 Sep; 46(9):459-65. PubMed ID: 18793576
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
Kothare PA; Linnebjerg H; Isaka Y; Uenaka K; Yamamura A; Yeo KP; de la Peña A; Teng CH; Mace K; Fineman M; Shigeta H; Sakata Y; Irie S
J Clin Pharmacol; 2008 Dec; 48(12):1389-99. PubMed ID: 19047364
[TBL] [Abstract][Full Text] [Related]
4. Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers.
Cui H; Zhao CY; Lv Y; Wei MJ; Zhu Y; Ma XZ; Xia YH; Tian JH; Ma Y; Liu Y; Zhang P; Xu M
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):265-275. PubMed ID: 33576936
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
Wang Y; Xu B; Zhu L; Lou K; Chen Y; Zhao X; Wang Q; Xu L; Guo X; Ji L; Cui Y; Fang Y
Clin Drug Investig; 2017 Dec; 37(12):1107-1115. PubMed ID: 28932995
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.
Iwamoto K; Nasu R; Yamamura A; Kothare PA; Mace K; Wolka AM; Linnebjerg H
Endocr J; 2009; 56(8):951-62. PubMed ID: 19706990
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
Calara F; Taylor K; Han J; Zabala E; Carr EM; Wintle M; Fineman M
Clin Ther; 2005 Feb; 27(2):210-5. PubMed ID: 15811484
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Henry RR; Logan D; Alessi T; Baron MA
Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
[TBL] [Abstract][Full Text] [Related]
10. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
11. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.
Soon D; Kothare PA; Linnebjerg H; Park S; Yuen E; Mace KF; Wise SD
J Clin Pharmacol; 2006 Oct; 46(10):1179-87. PubMed ID: 16988207
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.
Cui YM; Guo XH; Zhang DM; Tham LS; Tang CC; Mace K; Linnebjerg H
J Diabetes; 2013 Jun; 5(2):127-35. PubMed ID: 23332026
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal impairment on the pharmacokinetics of exenatide.
Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers.
Cui H; Zhao CY; Lv Y; Wei MJ; Zhu Y; Li Y; Xia YH; Liu Y; Tian JH; Zhang P
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):361-369. PubMed ID: 32006325
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Kolterman OG; Kim DD; Shen L; Ruggles JA; Nielsen LL; Fineman MS; Baron AD
Am J Health Syst Pharm; 2005 Jan; 62(2):173-81. PubMed ID: 15700891
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
Vlasakakis G; Johnson SL; Lin J; Yao X; Gruenloh CJ; Chism JP; Nunez DJ
Adv Ther; 2015 Jul; 32(7):650-61. PubMed ID: 26160357
[TBL] [Abstract][Full Text] [Related]
20. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Nelson P; Poon T; Guan X; Schnabel C; Wintle M; Fineman M
Diabetes Technol Ther; 2007 Aug; 9(4):317-26. PubMed ID: 17705687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
